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ABSTRACT
Although the efficacy of cysteinyl leukotriene receptor
antagonists in asthma therapy has been established
through controlled clinical trials, there are no data
concerning the effectiveness of their use in clinical
practice, in which there is no rigid selection based on
specific inclusion and exclusion criteria. The aim of the
present study was to evaluate the effectiveness of pran-
lukast in clinical practice. More than 2500 outpatients
with mild to severe persistent asthma answered an
input questionnaire, which consisted of 33 items
assessing asthma symptoms in terms of six activities of
daily living during the previous 2 weeks. Of these
patients, 1138 received treatment with pranlukast and
answered the same questionnaire 4–6 weeks after the
start of treatment. In 923 of these 1138 patients, we
examined the impact of concomitantly used inhaled
steroids, b 2-adrenergic agonists or sustained-release
theophylline on the effectiveness of pranlukast treat-
ment. One hundred and sixty-seven control patients
completed the questionnaire twice but did not receive
pranlukast treatment. We found a significant decrease
in the number of asthma symptoms reported among
both the 1138 patients treated with pranlukast and 
the 167 control patients. However, the magnitude of
the decrease in symptoms was significantly (P < 0.001)
greater with pranlukast treatment. Moreover, pranlukast
was equally efficacious in the presence and absence of
concomitantly used inhaled steroids, b 2-adrenergic
agonists or sustained-release theophylline. In conclu-
sion, pranlukast was shown to have clinical effective-
ness in the treatment of mild to severe persistent
asthma symptoms.
Key words: asthma, pranlukast, questionnaire, symp-
tom, treatment.
INTRODUCTION
The cysteinyl leukotrienes are potent airway contrac-
tile agonists1–4 that are known to be produced by
eosinophils5–7 and mast cells.8 They can be recovered
from body fluids of patients with asthma during induced9,10
or spontaneous11,12 asthma attacks. Cysteinyl leukotriene
receptor antagonists have been reported to cause signifi-
cant inhibition of cold air-,13 exercise-,14,15 allergen-16–18
and aspirin-induced19–21 asthma. The clinical efficacy of
these antagonists in the treatment of mild to moderate
asthma has been reported in rigorously controlled
studies.22–25 However, there are no data on the clinical
effectiveness of cysteinyl leukotriene receptor antago-
nists; that is, their use outside the setting of rigidly
controlled trials. Because effectiveness influences the use
of agents in a practice setting, we administered a ques-
tionnaire about asthma symptoms before and after
pranlukast administration to more than 1000 outpatients
with mild to severe chronic persistent asthma.
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METHODS
The present study was performed between October 1996
and March 1997 in the Tohoku district (Aomori, Akita,
Iwate, Miyagi, Yamagata and Fukushima prefectures) of
Japan. Two hundred and twenty-eight medical facilities,
ranging from private clinics to university hospitals, partic-
ipated in the study. Of all patients with mild to severe
persistent asthma who regularly attended these facilities,
2516 outpatients answered the first questionnaire at each
site. As shown in Table 1, the questionnaire consisted of
33 questions assessing asthma symptoms in terms of six
activities of daily living during the previous 2 weeks.
Of the 2516 outpatients who completed the ini-
tial questionnaire, 1138 (mean age (± SD) 54.0 ±
17.8 years; 591 males and 547 females) accepted treat-
ment with pranlukast and again answered the same
questionnaire 4–6 weeks after the start of treatment. In
923 of the 1138 patients treated with pranlukast, we
examined the impact of concomitantly used inhaled
steroids, b 2-adrenergic agonists or sustained-release
theophylline on the effectiveness of pranlukast treatment;
no subjects were excluded from the study on the basis of
medications used. Thus, pranlukast was administered in
a practice setting, because the role of post-marketing
effectiveness trials should be to inform physicians of the
clinical usefulness of administered agents under such
conditions and the efficacy of these receptor antagonists
has already been recognized by physicians through 
rigorously controlled studies. In addition, 167 outpatients
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Table 1 Thirty-three item questionnaire administered to patients with mild, moderate or severe persistent asthma at 228 medical
facilities in the Tohoku district of Japan
Circumstances Item
At rising 1. Cough
2. Sputum
3. Wheezing
4. Precordial oppression
5. Dyspnea
Preparing for the day or moving from place to place 6. Difficulty putting away bedding
7. Difficulty breathing when walking fast
8. Difficulty breathing when walking for a long time
9. Difficulty breathing when running
10. Difficulty breathing when going up and down stairs
11. Ill health on rainy or windy days
Outside the home (on the job, at school etc.) 12. Difficulty breathing during gymnastic class
13. Chest tightness when laughing loudly
14. Difficulty breathing during stress
15. Difficulty breathing in dusty places
16. Difficulty breathing when exercising lightly
At home 17. Difficulty breathing when carrying heavy items
18. Difficulty breathing when cleaning the house
19. Difficulty breathing when holding a child
20. Difficulty breathing when taking a bath
21. Difficulty breathing when taking a drink
22. Difficulty breathing when eating to the point of fullness
23. Difficulty breathing when playing with pets
24. Difficulty breathing in the presence of incense or perfume
Before sleep 25. Cough
26. Sputum
27. Wheezing
28. Precordial oppression
29. Dyspnea
During sleep 30. Difficulty putting down bedding
31. Inability to sleep well because of difficulty breathing
32. Trouble falling asleep because of difficulty breathing
33. Awakening during the night because of difficulty breathing
(mean age 51.0 ± 15.9 years; 74 males and 93 females)
who declined pranlukast treatment and continued to take
the same medication answered the second questionnaire
after the same interval.
Statistical analysis
Study subjects were divided into five groups on the
basis of the number of symptoms present (i.e. positive
questionnaire response to a query) on study initiation;
these groups were: (i) 0; (ii) 1–3; (iii) 4–8; (iv) 9–16; and
(v) ‡ 17. The Wilcoxon rank sum test was used to
examine differences in each group between responses 
to the first and second questionnaires. Analysis of variance
was used to compare responses of patients receiving
pranlukast with those of patients not receiving pranlukast
and to compare the effectiveness of pranlukast with
and without the concomitant use of inhaled steroids, 
b 2-adrenergic agonists or sustained-release theophylline.
RESULTS
As shown in Fig. 1, when subjects were arbitrarily divided
into five groups on the basis of the number of symptoms
reported, we found a significant improvement not only in
the 1138 patients (Fig. 1a) treated with pranlukast for
4–6 weeks but also in the 167 patients (Fig. 1b) who
answered the questionnaire on two occasions 4–6 weeks
apart without pranlukast treatment. As shown in Fig. 2,
the mean (± SEM) number of symptoms reported per
person in the pranlukast-treated group was 9.23 ± 0.18
and 4.81 ± 0.39 before and after treatment with pran-
lukast, respectively. The corresponding numbers in the
167 control patients were 6.25 ± 0.43 and 4.70 ±
0.14 at the time of completion of the first and second
questionnaires, respectively. Thus, the decrease in the
number of symptoms was significantly greater (P < 0.001)
in the pranlukast-treated group than in patients not
receiving pranlukast.
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Fig. 1 Symptom questionnaire results obtained on two occasions 4–6 weeks apart from patients with chronic asthma, 1138 of
whom received pranlukast and 167 of whom did not. At the time of administration of the second questionnaire, significant improve-
ment was evident in both (a) pranlukast-treated and (b) non-treated subjects. *P < 0.001 (Wilcoxon rank sum test).
Figure 3 shows changes in the number of symptoms
reported per patient before and after treatment with pran-
lukast in patients stratified by other asthma medication
use. The concomitant use of inhaled steroids (Fig. 3a; 
n = 372), b 2-adrenergic agonists (Fig. 3b; n = 602) or
sustained-release theophylline (Fig. 3c; n = 835) did not
modify the symptomatic response. Irrespective of the con-
comitant use of one of these three agents, pranlukast
treatment significantly (P < 0.001) decreased the number
of symptoms in all groups. Thus, we found no significant
difference in the efficacy of pranlukast with respect to the
concomitant use of these three agents.
There were no reported adverse effects of pranlukast,
although adverse effects were not included in the
outcome measures.
DISCUSSION
Our data indicate the effectiveness of pranlukast treat-
ment in clinical practice. We found a significantly greater
decrease in the number of symptoms reported by 1138
outpatients with mild to severe persistent asthma who
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Fig. 2 Mean (± SEM) number of symptoms in patients with
chronic asthma and the time of the first and second question-
naires. Results for 1138 pranlukast-treated patients are indicated
by the solid line, while those for 167 non-treated patients are
indicated by the dashed line. The decrease in number of symp-
toms was significantly greater among pranlukast-treated patients
compared with non-treated patients (P < 0.001).
Fig. 3 Mean (± SEM) numbers of symptoms in pranlukast-treated patients concomitantly taking (a) inhaled steroids (n = 372), 
(b) b 2-adrenergic agonists (n = 602) or (c) sustained-release theophylline (n = 835) are indicated by solid lines, while those in 
pranlukast-treated patients not taking these agents (n = 551, 321, and 88, respectively) are indicated by broken lines. Pranlukast
was equally effective in the presence and absence of these agents.
were treated with pranlukast, a cysteinyl leukotriene
receptor antagonist, compared with control patients,
although the control group had fewer symptoms than the
treatment group at the time of the first questionnaire.
Pranlukast treatment was associated with a decrease in
symptoms in all six activities of daily living. Treatment with
the drug resulted in a significant decrease in the number
of symptoms, irrespective of the concomitant use of
inhaled steroids, b 2-adrenergic agonists or sustained-
release theophylline. These findings demonstrate that
pranlukast is a useful agent for the relief of asthma symp-
toms in patients with chronic asthma, regardless of
alternative therapy.
The purpose of the present study was to examine the
clinical effectiveness of pranlukast in a practice setting on
a large number of patients with mild to severe persistent
asthma, because clinical usefulness22–25 of these receptor
antagonists has been reported only in rigorously con-
trolled studies. We used a questionnaire to obtain
information on both the impact of asthma on the every-
day lives of asthmatics26–28 and on the effects of treatment
in a large number of patients. There is no standard
method available for widespread use for assessing symp-
toms that is readily applicable to general practice.
Because some of the goals29 of asthma therapy are 
to prevent chronic symptoms, to maintain patients’ nor-
mal activity levels and to meet patients’ and families’
expectations for care, we designed our questionnaire to
enquire about 33 specific issues related to the activities of
daily life.
Because our questionnaire about asthma symptoms has
not been validated previously, we administered the ques-
tionnaire to 167 outpatients, who declined pranlukast
treatment but continued to take the same medications, on
two occasions 4–6 weeks apart. Although Juniper et al.26
have devised an asthma quality of life instrument, it is not
applicable for use in such a clinical practice setting. As
shown in Fig. 1, we found a significant decrease in the
number of symptoms in these 167 patients, despite the
lack of additional treatment. The reason for the improve-
ment in the control group may be that a clinical visit itself
improved compliance with medication, that administra-
tion of the questionnaire also improved compliance or
that symptom scores of the control group were lower than
those of the treatment group at the time of the first ques-
tionnaire. However, as shown in Fig. 2, the magnitude of
the improvement was significantly less marked than that
in the pranlukast-treated group. Interestingly, the group
who refused pranlukast treatment had fewer asthma
symptoms than those who accepted it at the time of the
first questionnaire and the final level of symptoms was
similar in both groups. Thus, our findings demonstrate
that pranlukast significantly decreased asthma symptoms
to a minimal level in patients with persistent asthma.
Although inhaled corticosteroids are potent and
effective agents currently available for the treatment 
of mild, moderate or severe persistent asthma, these
agents do not completely control asthma. In the
present study, we demonstrated that pranlukast treat-
ment significantly decreased the symptoms of asthma,
irrespective of the concomitant use of inhaled ster-
oids, b 2-adrenergic agonists or sustained-release theo-
phylline. It is not surprising that pranlukast improved
the clinical condition of asthmatics concurrently using
inhaled corticosteroids, because corticosteroids have
been reported not to inhibit the production of cysteinyl
leukotrienes in both in vitro30,31 and in vivo studies.32
Although the position of this class of drugs in asthma
therapy has not been fully established, our findings indi-
cate that pranlukast has clinical effectiveness in the
treatment of symptoms in mild to severe persistent
asthma. Because the clinical effectiveness would be
seen with any leukotriene modifiers, this class of agent
is likely to be of value in the global treatment of asthma.
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